Lipemia retinalis following FLAG-Ida protocol in an 11-year-old patient with acute myeloid leukemia

被引:0
|
作者
Koruk, Reyhan Hazal Kaplan [1 ]
Kocabora, Mehmet Selim [2 ]
Erdur, Sevil Karaman [2 ]
Yaman, Yontem [3 ]
机构
[1] Istanbul Training & Res Hosp, Dept Ophthalmol, Org Abdurrahman Nafiz Gurman St 24, TR-34098 Istanbul, Turkiye
[2] Istanbul Medipol Univ, Fac Med, Dept Ophthalmol, Istanbul, Turkiye
[3] Istanbul Medipol Univ, Fac Med, Dept Pediat Hematol & Oncol, Istanbul, Turkiye
关键词
Vitreous/retinal disease; PEDIATRIC OPHTHALMOLOGY; pharmacology; PHARMACOLOGY; practice management; SOCIOECONOMICS AND EDUCATION IN MEDICINE/OPHTHALMOLOGY; systemic drug retinal toxicity; RETINA; retinal pathology / research; AML; FLAG-Ida; hypertriglyceridemia; hypercholesterolemia; leukemia; lipemia retinalis;
D O I
10.1177/11206721241287347
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Introduction We report a case of early-onset lipemia retinalis secondary to the FLAG-Ida protocol in the treatment of acute myeloid leukemia (AML) in an 11-year-old girl.Case Report An 11-year-old patient, diagnosed with AML at four months old, experienced a relapse and was treated with the FLAG-Ida protocol (fludarabine, idarubicin, granulocyte-colony stimulating factor, and high-dose cytarabine). Prior to allogeneic stem cell transplantation, she underwent a pre-transplantation eye examination. The patient exhibited normal visual acuity in both eyes. Fundus examination revealed cream-white retinal vessels and a salmon-pink retina, indicative of grade 3 lipemia retinalis. Laboratory tests, normal before treatment initiation, showed significantly elevated serum cholesterol (727.6 mg/dL) and triglyceride (6015.6 mg/dL) levels post-treatment. After receiving fenofibrate, these levels decreased markedly, and the retinal vessels normalized on follow-up fundus examination.Conclusion Lipemia retinalis, characterized by creamy-white retinal vessels resulting from hypertriglyceridemia, can develop as a secondary condition to chemotherapy. Early detection and treatment of hyperlipidemia are crucial to prevent severe ocular and systemic complications. This case highlights the importance of monitoring lipid levels and conducting thorough ophthalmologic examinations in patients undergoing chemotherapy.
引用
收藏
页码:NP5 / NP9
页数:5
相关论文
共 15 条
  • [1] Fetal Loss in a Patient with Acute Myeloblastic Leukemia Associated with FLAG-IDA Regime
    Pasa, Semir
    Altintas, Abdullah
    Cil, Timucin
    Ayyildiz, Orhan
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2009, 19 (02): : 110 - 112
  • [2] FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience
    D. Pastore
    G. Specchia
    P. Carluccio
    A. Liso
    A. Mestice
    R. Rizzi
    G. Greco
    C. Buquicchio
    V. Liso
    Annals of Hematology, 2003, 82 : 231 - 235
  • [3] FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients
    Delia, Mario
    Pastore, Domenico
    Cariuccio, Paola
    Paseiolla, Crescenza
    Ricco, Alessandra
    Rossi, Antonella Russo
    Casieri, Paola
    Mestice, Anna
    Albano, Francesco
    Specchia, Giorgina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (11): : 767 - 773
  • [4] FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience
    Pastore, D
    Specchia, G
    Carluccio, P
    Liso, A
    Mestice, A
    Rizzi, R
    Greco, G
    Buquicchio, C
    Liso, V
    ANNALS OF HEMATOLOGY, 2003, 82 (04) : 231 - 235
  • [5] Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia
    Shargian-Alon, Liat
    Wolach, Ofir
    Rozovski, Uri
    Yahav, Dafna
    Sela-Navon, Michal
    Rubinstein, Mazal
    Oniashvilli, Nino
    Pasvolsky, Oren
    Raanani, Pia
    Yeshurun, Moshe
    ANNALS OF HEMATOLOGY, 2020, 99 (12) : 2939 - 2945
  • [6] A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
    María P. Martínez Sánchez
    Juan Eduardo Megías-Vericat
    Rebeca Rodríguez-Veiga
    Susana Vives
    Juan Miguel Bergua
    Anna Torrent
    Sara Suárez-Varela
    Blanca Boluda
    Joaquín Martínez-López
    Isabel Cano-Ferri
    Evelyn Acuña-Cruz
    Laura Torres-Miñana
    Beatriz Martín-Herreros
    Alfons Serrano
    Amparo Sempere
    Eva Barragán
    Claudia Sargas
    Miguel Sanz
    David Martínez-Cuadrón
    Pau Montesinos
    Annals of Hematology, 2021, 100 : 1497 - 1508
  • [7] Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
    DiNardo, Courtney D.
    Lachowiez, Curtis A.
    Takahashi, Koichi
    Loghavi, Sanam
    Xiao, Lianchun
    Kadia, Tapan
    Daver, Naval
    Adeoti, Maria
    Short, Nicholas J.
    Sasaki, Koji
    Wang, Sa
    Borthakur, Gautam
    Issa, Ghayas
    Maiti, Abhishek
    Alvarado, Yesid
    Pemmaraju, Naveen
    Bravo, Guillermo Montalban
    Masarova, Lucia
    Yilmaz, Musa
    Jain, Nitin
    Andreeff, Michael
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Kornblau, Steven
    Ravandi, Farhad
    Konopleva, Marina Y.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (25) : 2768 - +
  • [8] A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
    Martinez Sanchez, Maria P.
    Megias-Vericat, Juan Eduardo
    Rodriguez-Veiga, Rebeca
    Vives, Susana
    Bergua, Juan Miguel
    Torrent, Anna
    Suarez-Varela, Sara
    Boluda, Blanca
    Martinez-Lopez, Joaquin
    Cano-Ferri, Isabel
    Acuna-Cruz, Evelyn
    Torres-Minana, Laura
    Martin-Herreros, Beatriz
    Serrano, Alfons
    Sempere, Amparo
    Barragan, Eva
    Sargas, Claudia
    Sanz, Miguel
    Martinez-Cuadron, David
    Montesinos, Pau
    ANNALS OF HEMATOLOGY, 2021, 100 (06) : 1497 - 1508
  • [9] Comparison of HiDAC Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Tang, Man Wai
    van der Tuin, Deborah
    Aydin, Mesire
    Heijmans, Jarom
    van de Loosdrecht, Arjan A.
    Meijer, Ellen
    Rutten, Caroline E.
    Wondergem, Marielle
    Janssen, Jeroen J. W. M.
    Donker, Marjolein L.
    Hazenberg, Mette D.
    Zweegman, Sonja
    Biemond, Bart J.
    De Leeuw, David C.
    Nur, Erfan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (04) : 620 - 625
  • [10] Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia
    Dinardo, Courtney D.
    Jen, Wei-Ying
    Takahashi, Koichi
    Kadia, Tapan M.
    Loghavi, Sanam
    Daver, Naval G.
    Xiao, Lianchun
    Reville, Patrick K.
    Issa, Ghayas C.
    Short, Nicholas J.
    Sasaki, Koji
    Wang, Sa A.
    Mullin, Jillian K.
    Pierce, Sherry
    Bradley, Corey
    Borthakur, Gautam
    Maiti, Abhishek
    Alvarado, Yesid
    Pemmaraju, Naveen
    Ferrajoli, Alessandra
    Swaminathan, Mahesh
    Ohanian, Maro
    Abbas, Hussein A.
    Hammond, Danielle
    Burger, Jan
    Haddad, Fadi
    Montalban-Bravo, Guillermo
    Chien, Kelly
    Masarova, Lucia
    Yilmaz, Musa
    Jain, Nitin
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Kornblau, Steven
    Ravandi, Farhad
    Jabbour, Elias
    Konopleva, Marina Y.
    Kantarjian, Hagop M.
    LEUKEMIA, 2025, : 854 - 863